Bayer: Group performance matches prior year despite declines at Crop Science
Group sales increase by 3.0 percent (Fx& portfolio adj.: plus 1.9 percent) to EUR 12,193 million / EBITDA before special items level with the prior year, at EUR 3,056 million
(plus 0.1 percent) / Pharmaceuticals posts strong increase in earnings and margins / Brazil business weighs on Crop Science / Consumer Health encounters difficult market environment in the United States / Significant increase in sales and earnings at Covestro / Net income decreases by 11.3 percent to EUR 1,224 million / Core earnings per share EUR 1.81 (minus 12.6 percent) / Monsanto acquisition on track / Group outlook for 2017 adjusted (Source: Bayer Company News)
Source: Bayer Company News - July 27, 2017 Category: Pharmaceuticals Source Type: news
Phase II Trial of Investigational Anetumab Ravtansine Does Not Meet Primary Endpoint in Second-Line Mesothelioma (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - July 21, 2017 Category: Pharmaceuticals Source Type: news
Bayer ’s Xarelto in Combination with Single Antiplatelet Therapy Receives Positive CHMP Opinion for Treatment of Patients with Atrial Fibrillation requiring oral Anticoagulation and undergoing Percutaneous Coronary Intervention with Stent Placement (for specialized target groups only)
Positive CHMP Opinion is based on data from the Phase IIIb PIONEER AF-PCI study, which demonstrated significantly reduced rates of clinically significant bleeding with Xarelto compared with VKA in patients with non-valvular atrial fibrillation (AF) who require oral anticoagulation and are also receiving antiplatelet therapy after percutaneous coronary intervention (PCI) with stent placement (1) / PIONEER AF-PCI is the first and currently only randomised clinical trial of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Final decision of European Commission expected by the end of this year (...
Source: Bayer Company News - July 21, 2017 Category: Pharmaceuticals Source Type: news
Bayer invests 92 million euros in Animal Health production
Program for expanding site in Kiel, Germany, until 2021 (Source: Bayer Company News)
Source: Bayer Company News - July 3, 2017 Category: Pharmaceuticals Source Type: news
Bayer starts Phase III study program with Vilaprisan in the treatment of symptomatic uterine fibroids (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - July 3, 2017 Category: Pharmaceuticals Source Type: news
Bayer expects negative earnings impact from its Brazilian Crop Science business
(Source: Bayer Company News)
Source: Bayer Company News - June 30, 2017 Category: Pharmaceuticals Source Type: news
Bayer Receives Approval for Stivarga ® in Japan for Second-Line Treatment of Hepatocellular Carcinoma (for specialized target groups only)
Stivarga ® (regorafenib) is the first and only systemic treatment to demonstrate significant improvement in overall survival in second-line hepatocellular carcinoma (HCC) patients and the first treatment advance in nearly a decade / Pivotal trial RESORCE defines a new treatment plan in hepatocellular carcin oma (HCC) with Stivarga directly after Nexavar® (sorafenib) (Source: Bayer Company News)
Source: Bayer Company News - June 26, 2017 Category: Pharmaceuticals Source Type: news
Bayer Receives Positive CHMP Opinion for regorafenib for the Second-Line Systemic Treatment of Liver Cancer (for specialized target groups only)
Positive opinion based on data from the Phase III RESORCE study, in which regorafenib demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar ® (sorafenib) / Approval could provide first treatment advance in nearly a decade / Final decision from the European Commission anticipated within the next two months (Source: Bayer Company News)
Source: Bayer Company News - June 23, 2017 Category: Pharmaceuticals Source Type: news
Bayer places 8.5 percent of Covestro ’s shares and EUR 1 billion bonds exchangeable into Covestro shares
(Source: Bayer Company News)
Source: Bayer Company News - June 7, 2017 Category: Pharmaceuticals Source Type: news
Bayer further reduces stake in Covestro
Accelerated bookbuilding and bonds exchangeable into Covestro shares offered / Bayer to deposit 8 million Covestro shares in Bayer Pension Trust e. V. (Source: Bayer Company News)
Source: Bayer Company News - June 6, 2017 Category: Pharmaceuticals Source Type: news
Bayer Receives FDA Priority Review For Investigational Anti-Cancer Compound Copanlisib (for specialized target groups only)
Regulatory submission based on data from the Phase II CHRONOS-1 study, in which copanlisib showed objective response rate of 59% and a manageable safety profile in patients with follicular lymphoma (FL) / Copanlisib is an intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant activity against PI3K-α and PI3K-δ isoforms / Copanlisib granted Fast Track and Orphan Drug Designation in the U.S. for FL (Source: Bayer Company News)
Source: Bayer Company News - May 17, 2017 Category: Pharmaceuticals Source Type: news
Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism (for specialized target groups only)
If approved, rivaroxaban 10 mg once daily will provide an additional treatment option alongside the already approved rivaroxaban 20 mg once-daily dose / Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped / Application to FDA supported by data from the EINSTEIN CHOICE study (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2017 Category: Pharmaceuticals Source Type: news
